文献速递眼底病与葡萄膜炎白内障与屈光手术

质子治疗避免眼黑色素瘤患者白内障

Cataract Avoidance With Proton Therapy in Ocular Melanomas.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2017-01-01

研究纳入1991至2015年连续接受质子治疗的1696例葡萄膜黑色素瘤患者,前瞻性数据库记录晶状体剂量与白内障发生。中位随访48个月,14.4%发生白内障、8.7%发生视力损害性白内障;当受照晶状体体积≤5%时,剂量低于10 GyRBE未见视力损害性白内障风险显著增加。作者认为保留晶状体的方法可行,可减少白内障手术需求并改善眼底肿瘤控制。

要点

  • 中位随访48个月,1696例葡萄膜黑色素瘤患者中14.4%发生白内障,8.7%发生视力损害性白内障。
  • 受照晶状体体积≤5%时,剂量低于10 GyRBE未见视力损害性白内障风险显著增加。
  • 25%的患者晶状体未接受任何剂量,保留晶状体方法可行。

核心结论

  • 保留晶状体的质子治疗方法可行,不仅减少白内障手术需求,还改善基于眼底的肿瘤控制,后续可能重新评估晶状体剂量阈值的辐射防护规则。

研究设计与样本

  • 前瞻性数据库纳入1991至2015年连续接受质子治疗的1696例葡萄膜黑色素瘤患者,由私人和学术机构的肿瘤眼科医生转诊,排除已有白内障或植入物的患者。
  • 眼科医生对晶状体剂量设盲,每半年随访晶状体混浊和新发视力损害性白内障,采用单因素和多因素回归分析剂量-体积关系与视力损害性白内障的相关性。

主要发现

  • 中位随访48个月,14.4%的患者发生白内障,8.7%发生视力损害性白内障,中位发生时间分别为19个月和28个月。
  • 晶状体平均剂量中位值为1.1 GyRBE(光子等效灰度的相对生物效应剂量),晶状体周边剂量中位值为6.5 GyRBE。
  • 25%的患者晶状体未接受任何剂量。
  • 当受照晶状体体积≤5%时,剂量低于10 GyRBE未见视力损害性白内障风险显著增加。

关键数值与推荐

  • 受照晶状体体积≤5%且剂量低于10 GyRBE时,视力损害性白内障风险未见显著增加。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The lens is a radiosensitive organ. Any dose of cephalic irradiation can give rise to radiation-induced cataracts. Contrary to other forms of radiotherapy, proton therapy (PT) can spare all or part of the lens due to accurate dose deposition. We investigated whether a lens-sparing approach was relevant to avoid cataracts in uveal melanoma patients. METHODS: Patients were referred for PT from onco-ophthalmologists of private and academic institutions. Patients without preexisting cataracts or implants were entered in a prospective database. Dose thresholds responsible for cataracts were investigated in volumes of lens or lens periphery. Lens opacifications and de novo vision-impairing cataracts (VICs) had biannual follow up by ophthalmologists blinded to lens dose. Correlations between dose-volume relationships and VICs were assessed using univariate/multivariate regressions. RESULTS: Between 1991 and 2015, 1696 uveal melanoma patients were consecutively treated with PT. After a median follow up of 48 months, 14.4% and 8.7% of patients had cataracts and VIC within median times of 19 and 28 months, respectively. Median values of mean lens and lens periphery doses were 1.1 (radiobiologically effective [RBE] dose in photon-equivalent grays [GyRBE]) and 6.5 GyRBE, respectively. The lens received no dose in 25% of the patients. At an irradiated lens volume of ≤5%, there was no significantly increased risk for VIC below a dose of 10 GyRBE. CONCLUSIONS: A lens-sparing approach is feasible and results not only in reduced need for cataract surgery but also in better fundus-based tumor control. Reassessment of radioprotection rules for lens dose thresholds may follow.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Thariat J, Jacob S, Caujolle JP, et al. Cataract Avoidance With Proton Therapy in Ocular Melanomas. Invest Ophthalmol Vis Sci. 2017. PMID: 29049739. doi:10.1167/iovs.17-22557

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。